🎁 $75,000 HOLIDAY MATCH IS LIVE🎁

Make a gift during the season of giving!

EOY Giving 2025 Match Your Gift

Targeted ‘radioligand’ improves survival in advanced prostate cancer

cells

Cancer researchers say they have established a new, life-extending treatment option for men with prostate cancer that has spread and become resistant to hormone therapy. The injected treatment combines a targeting compound with a radioactive isotope to irradiate and kill cancer cells.

Read the full article here

Share